EP4247430A4 - Her3 radioimmunotherapy for the treatment of solid cancers - Google Patents

Her3 radioimmunotherapy for the treatment of solid cancers Download PDF

Info

Publication number
EP4247430A4
EP4247430A4 EP21895766.0A EP21895766A EP4247430A4 EP 4247430 A4 EP4247430 A4 EP 4247430A4 EP 21895766 A EP21895766 A EP 21895766A EP 4247430 A4 EP4247430 A4 EP 4247430A4
Authority
EP
European Patent Office
Prior art keywords
radioimmunotherapy
her3
treatment
solid cancers
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21895766.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4247430A1 (en
Inventor
Dale L Ludwig
Eileen GEOGHEGAN
Sandesh SETH
Paul Diamond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinium Pharmaceuticals Inc
Original Assignee
Actinium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/056259 external-priority patent/WO2022087416A1/en
Application filed by Actinium Pharmaceuticals Inc filed Critical Actinium Pharmaceuticals Inc
Publication of EP4247430A1 publication Critical patent/EP4247430A1/en
Publication of EP4247430A4 publication Critical patent/EP4247430A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP21895766.0A 2020-11-20 2021-11-22 Her3 radioimmunotherapy for the treatment of solid cancers Pending EP4247430A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063116225P 2020-11-20 2020-11-20
US202063118181P 2020-11-25 2020-11-25
US202163226699P 2021-07-28 2021-07-28
US202163250725P 2021-09-30 2021-09-30
PCT/US2021/056259 WO2022087416A1 (en) 2020-10-22 2021-10-22 Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
PCT/US2021/060370 WO2022109404A1 (en) 2020-11-20 2021-11-22 Her3 radioimmunotherapy for the treatment of solid cancers

Publications (2)

Publication Number Publication Date
EP4247430A1 EP4247430A1 (en) 2023-09-27
EP4247430A4 true EP4247430A4 (en) 2024-12-11

Family

ID=81709768

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21895766.0A Pending EP4247430A4 (en) 2020-11-20 2021-11-22 Her3 radioimmunotherapy for the treatment of solid cancers

Country Status (8)

Country Link
EP (1) EP4247430A4 (https=)
JP (1) JP2023550462A (https=)
KR (1) KR20230128271A (https=)
AU (1) AU2021382717A1 (https=)
CA (1) CA3199259A1 (https=)
IL (1) IL303030A (https=)
MX (1) MX2023005940A (https=)
WO (1) WO2022109404A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022087416A1 (en) * 2020-10-22 2022-04-28 Actinium Pharmaceuticals, Inc. Combination radioimmunotherapy and cd47 blockade in the treatment of cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022000A2 (en) * 2000-09-15 2002-03-21 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US20100183631A1 (en) * 2005-12-30 2010-07-22 Mike Rothe Antibodies Directed to HER-3 and Uses Thereof
WO2011022727A2 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
US20120156130A1 (en) * 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
WO2020132672A1 (en) * 2018-12-21 2020-06-25 Actinium Pharmaceuticals, Inc. Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022000A2 (en) * 2000-09-15 2002-03-21 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US20100183631A1 (en) * 2005-12-30 2010-07-22 Mike Rothe Antibodies Directed to HER-3 and Uses Thereof
WO2011022727A2 (en) * 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of erbb3 and uses thereof
US20120156130A1 (en) * 2010-08-06 2012-06-21 Thore Hettmann Use of her3 binding agents in prostate treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BORCHARDT PAUL E ET AL: "Targeted actinium-225 in vivo generators for therapy of ovarian cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CA . PHILADELPHIA (PA, vol. 63, no. 16, 15 August 2003 (2003-08-15), pages 5084 - 5090, XP002458367, ISSN: 0008-5472 *
HIDEKAZU KAWASHIMA: "Radioimmunotherapy: A Specific Treatment Protocol for Cancer by Cytotoxic Radioisotopes Conjugated to Antibodies", THE SCIENTIFIC WORLD JOURNAL, vol. 2014, 1 January 2014 (2014-01-01), pages 1 - 10, XP055522090, ISSN: 2356-6140, DOI: 10.1155/2014/492061 *
ORLOVA ANNA ET AL: "Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab", MOLECULAR PHARMACEUTICS, vol. 15, no. 8, 11 July 2018 (2018-07-11), US, pages 3394 - 3403, XP093066490, ISSN: 1543-8384, DOI: 10.1021/acs.molpharmaceut.8b00393 *
See also references of WO2022109404A1 *
YOSHII YUKIE ET AL: "Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64 Culabeled cetuximab to treat early-and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts", ONCOTARGET, vol. 9, no. 48, 22 June 2018 (2018-06-22), United States, pages 28935 - 28950, XP093148547, ISSN: 1949-2553, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034757/pdf/oncotarget-09-28935.pdf> *

Also Published As

Publication number Publication date
AU2021382717A9 (en) 2025-03-13
AU2021382717A1 (en) 2023-07-06
CA3199259A1 (en) 2022-05-27
IL303030A (en) 2023-07-01
EP4247430A1 (en) 2023-09-27
MX2023005940A (es) 2023-07-27
JP2023550462A (ja) 2023-12-01
WO2022109404A1 (en) 2022-05-27
KR20230128271A (ko) 2023-09-04

Similar Documents

Publication Publication Date Title
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
EP3634417A4 (en) CHINAZOLINE PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA43640A (fr) Inhibiteurs de idh1 pour le traitement de cancers hématologiques et de tumeurs solides
EP3781564C0 (en) PYRIDAZINE DERIVATIVES FOR TREATING CANCER
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3570844A4 (en) AZOLOPYRIMIDINE FOR TREATING CANCER-BASED DISEASES
EP3728271A4 (en) MACROCYCLIC COMPOUNDS FOR DISEASE TREATMENT
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
EP3500285A4 (en) COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIC PAIN AND FOR THE SENSITIZATION OF TUMORS ON CHEMOTHERAPY
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR CANCER TREATMENT
MA50409A (fr) Polythérapies pour le traitement du cancer
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3454896A4 (en) HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV
EP3541417A4 (en) Combination immunotherapies for treatment of cancer
EP3863671A4 (en) MONOCLONAL ANTIBODY FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EP3947460A4 (en) MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
MA46086A (fr) Schéma posologique pour le traitement de tumeurs solides
EP3749342A4 (en) BACTERIOPHAGE FOR THE TREATMENT AND PREVENTION OF CARCINOMAS ASSOCIATED WITH BACTERIA
EP4373525A4 (en) CANCER TREATMENT COMBINATIONS
EP3793544A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230619

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40094744

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047640000

Ipc: A61K0051080000

A4 Supplementary search report drawn up and despatched

Effective date: 20241108

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20241104BHEP

Ipc: C07K 16/28 20060101ALI20241104BHEP

Ipc: A61P 35/00 20060101ALI20241104BHEP

Ipc: A61K 51/10 20060101ALI20241104BHEP

Ipc: A61K 45/06 20060101ALI20241104BHEP

Ipc: A61K 39/00 20060101ALI20241104BHEP

Ipc: A61K 39/395 20060101ALI20241104BHEP

Ipc: C07K 14/47 20060101ALI20241104BHEP

Ipc: A61K 47/64 20170101ALI20241104BHEP

Ipc: A61K 51/08 20060101AFI20241104BHEP